{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=59", "query": { "condition": "Melanoma Neoplasms", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 2208, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T20:22:45.588Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06168825", "title": "Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Breast Cancer", "Brain Cancer", "Central Nervous System Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gynecologic Cancer", "Head and Neck Cancer", "Gastrointestinal Cancer", "Genitourinary Cancer", "Melanoma", "Blood Cancer", "Lung Cancer", "Acceptance and Commitment Therapy", "Mind-Body Therapies", "Psychosocial Intervention" ], "interventions": [ { "name": "Mind Over Matter (MOM)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-01-17", "completion_date": "2024-06-04", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Fairfax, Virginia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06168825" }, { "nct_id": "NCT07287917", "title": "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "HER2-low Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "AMXT 1501 Dicaprate", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2026-01-26", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287917" }, { "nct_id": "NCT02482168", "title": "Study of the CD40 Agonistic Monoclonal Antibody APX005M", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "NSCLC", "Melanoma", "Urothelial Carcinoma", "MSI-H", "Head and Neck Cancer" ], "interventions": [ { "name": "APX005M", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apexigen America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-05", "completion_date": "2018-06-19", "has_results": false, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 3, "location_summary": "Duarte, California • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02482168" }, { "nct_id": "NCT01657591", "title": "Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "XL888", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-07-27", "completion_date": "2021-09-21", "has_results": false, "last_update_posted_date": "2023-01-19", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01657591" }, { "nct_id": "NCT07327489", "title": "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Immunotherapy", "Advanced Solid Tumors Cancer", "Bladder Cancer", "TNBC, Triple Negative Breast Cancer", "Colorectal Cancer", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Endometrial Cancer", "Head and Neck Cancer", "Kidney Cancer", "Liver Cancer", "NSCLC (Non-small-cell Lung Cancer)", "Skin Cancer", "Melanoma (Skin Cancer)" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2025-04-14", "completion_date": "2038-04", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 8, "location_summary": "Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Springfield", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07327489" }, { "nct_id": "NCT00350597", "title": "GM-CSF as Adjuvant Therapy of Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northern California Melanoma Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 50, "start_date": "2004-09", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2006-07-11", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350597" }, { "nct_id": "NCT04697576", "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Nivolumab + Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Carlo Contreras", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2021-10-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697576" }, { "nct_id": "NCT00003750", "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)", "Neuroblastoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "hu14.18-IL2 fusion protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 28, "start_date": "2001-10", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 54, "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003750" }, { "nct_id": "NCT03154190", "title": "Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Brain Glioblastoma", "Estrogen Receptor Negative", "Extensive Stage Small Cell Lung Carcinoma", "Head and Neck Carcinoma", "HER2/Neu Negative", "Hormone-Resistant Prostate Cancer", "Limited Stage Small Cell Lung Carcinoma", "Myelodysplastic Syndrome", "Progesterone Receptor Negative", "Progressive Disease", "Recurrent Carcinoma", "Stage II Pancreatic Cancer", "Stage II Rectal Cancer", "Stage IIA Pancreatic Cancer", "Stage IIA Rectal Cancer", "Stage IIB Pancreatic Cancer", "Stage IIB Rectal Cancer", "Stage IIC Rectal Cancer", "Stage III Colon Cancer", "Stage III Esophageal Cancer", "Stage III Gastric Cancer", "Stage III Non-Small Cell Lung Cancer", "Stage III Ovarian Cancer", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Skin Melanoma", "Stage IIIA Colon Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Rectal Cancer", "Stage IIIA Skin Melanoma", "Stage IIIB Colon Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Rectal Cancer", "Stage IIIB Skin Melanoma", "Stage IIIC Colon Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Rectal Cancer", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Bone Sarcoma", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Ovarian Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IV Soft Tissue Sarcoma", "Stage IVA Bone Sarcoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Bone Sarcoma", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Supportive Care", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2017-08-08", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03154190" }, { "nct_id": "NCT04792463", "title": "Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Uveal Melanoma", "Cutaneous Melanoma", "BAP1 Gene Mutation", "Renal Cell Carcinoma", "Mesothelioma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Meningioma Atypical" ], "interventions": [], "intervention_types": [], "sponsor": "Mohamed Abdel-Rahman", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 500, "start_date": "2015-03-03", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-26T20:22:45.588Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04792463" } ] }